The project aims are evaluate the sensitivity and different inhibitors of the PARP molecule in a comparative way and study the mechanisms of resistance, as well as to identify possible markers predictive of the response pharmacological.
Despite a European effort to apply next generation genetic/molecular analysis techniques to pediatric solid tumours, cure rates remain poor and a significant percentage of tumors have no obvious drug target. Recent pediatric cancer studies suggest that a large proportion of Ewing's sarcoma, osteosarcoma, glioblastoma, medulloblastoma, neuroblastoma, and rhabdomyosarcoma, display a mutational signature known as BRCAness.
The project uses representative experimental models of pediatric tumors (e.g. PDX) and aims to evaluate the sensitivity to different inhibitors of the PARP molecule in a comparative way and to study the mechanisms of resistance, as well as to identify possible markers predictive of the response pharmacological.
The results of this preclinical study will lay the foundations for the design of clinical studies on pediatric solid tumors within the European Innovative Therapies for Children with Cancer (ITCC) network.
Project: BRCADDICT – BRCAness come Bersaglio Terapeutico in Tumori Solidi Pediatrici ad Alto Rischio
Acronym: BRCADDICT
Funding Program: ERA-NET: Aligning national/regional translational cancer research programmes and activities - TRANSCAN-2
Call: Joint Transnational Call for Proposals 2017 (JTC 2017) on "Traslational research on rare cancers"
Duration: 01/01/2017-30-06-2023
Coordinator: German Cancer Research Center Heidelberg
Coordinator Scientific IOR: Katia Scotlandi
Budget IOR: 164.991,85€
